Gross margin
55.3% Fiscal year 2025
Rank 58 of 100: higher than 58% of 153 peers (All). medium.
Rank 23 of 100: higher than 23% of 20 peers (Sector). weak.
Median Health Care: 66.6%
Share of revenue left after the direct cost of the products sold.
About the company
Moderna is a US biotech company built on mRNA technology. It became known for its Covid-19 vaccine. It also develops vaccines against RSV and flu as well as cancer and other therapies based on mRNA. As of Oct 11, 2026
Fact sheet (from the annual report) Biotechnology and vaccines · Cambridge, USA
The company develops mRNA-based vaccines and therapies for infectious diseases, oncology and rare diseases. It markets the vaccines Spikevax and mNEXSPIKE against COVID and mRESVIA against the respiratory virus RSV. Revenue in 2025 came largely from the COVID vaccines. According to the company, mNEXSPIKE, launched in 2025, was ahead of its other products in the US retail channel as of the report. Its research comprises programs in infectious diseases, oncology and rare diseases, partly together with Merck.
Automatically summarized from SEC annual report (10-K, filed Feb 20, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026
Price performance at a glance
Last 30 trading days
- Today +4.6%
- 7 days −14.1%
- 30 days +4.6%
- 1 year +680.1%
Day range (last trading day)
−13.7%Price at 97% of the range+0.4%
52-week range
−89.3%Price at 80% of the range+22.4%
- Distance from the all-time high
- −58.2%
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Double bottom · Analysis method
This method currently detects no pattern for MRNA. The check runs daily after the close.
You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing
What does the pattern show?
What is this? The price has formed two similarly deep lows and broken above the neckline between them. This is seen as a sign that the downward move is ending.
This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and marginModerna · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 20, 2026.
Quality checks
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
Quality
Profitability, consistency, balance sheet
2 of 8 criteria met
Growth
Revenue and earnings per share · 3 without data
1 of 4 criteria met
Dividend
Level, consistency, coverage · 6 without data
0 of 1 criteria met
Financial strength
Piotroski, debt, liquidity
4 of 6 criteria met
Quality 2 of 8 met
- met: Gross margin above 40% 55.3%
- not met: Operating margin above 15% −158.1%
- not met: Net margin above 10% −145.2%
- not met: Return on equity above 15% −32.6%
- not met: Free cash flow margin above 10% −106.2%
- not met: Profit in each of the last 5 fiscal years 2 of 5
- not met: Free cash flow positive in each of the last 3 fiscal years 0 of 3
- met: Equity ratio above 30% 70.1%
Operating margin
−158.1% Fiscal year 2025
Rank 6 of 100: higher than 6% of 192 peers (All). weak.
Rank 8 of 100: higher than 8% of 20 peers (Sector). weak.
Median Health Care: 18.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
−145.2% Fiscal year 2025
Rank 7 of 100: higher than 7% of 237 peers (All). weak.
Rank 10 of 100: higher than 10% of 26 peers (Sector). weak.
Median Health Care: 13.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
−32.6% Fiscal year 2025
Rank 7 of 100: higher than 7% of 218 peers (All). weak.
Rank 7 of 100: higher than 7% of 21 peers (Sector). weak.
Median Health Care: 14.3%
Net income divided by equity at fiscal year end.
Return on assets
−22.9% Fiscal year 2025 (total assets at year end)
Rank 6 of 100: higher than 6% of 238 peers (All). weak.
Rank 10 of 100: higher than 10% of 26 peers (Sector). weak.
Median Health Care: 6.4%
Net income divided by total assets at fiscal year end.
Equity ratio
70.1% Fiscal year 2025
Rank 89 of 100: higher than 89% of 239 peers (All). strong.
Rank 83 of 100: higher than 83% of 26 peers (Sector). strong.
Median Health Care: 38.5%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
−106.2% Fiscal year 2025
Rank 9 of 100: higher than 9% of 213 peers (All). weak.
Rank 10 of 100: higher than 10% of 25 peers (Sector). weak.
Median Health Care: 14.9%
Free cash flow divided by revenue.
Free cash flow
−2.1B USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 1 of 4 met · 3 without data
- not met: Over 3 years, revenue grew by more than 5% per year −53.4%
- met: Over 5 years, revenue grew by more than 5% per year +19.3%
- no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
- no data: Over 3 years, EPS grew by more than 5% per year not computable (loss in the first or last year, or figures missing)
- no data: Over 5 years, EPS grew by more than 5% per year not computable (loss in the first or last year, or figures missing)
- not met: Revenue rose in at least 4 of the last 5 fiscal years 2 of 5
- not met: Revenue rose in the last fiscal year −39.9%
Revenue growth 3 years
−53.4% per year
Rank 0 of 100: higher than 0% of 230 peers (All). weak.
Rank 2 of 100: higher than 2% of 25 peers (Sector). weak.
Median Health Care: +5.6%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+19.3% per year
Rank 74 of 100: higher than 74% of 217 peers (All). strong.
Rank 90 of 100: higher than 90% of 25 peers (Sector). strong.
Median Health Care: +8.5%
Average growth per year over 5 fiscal years.
Dividend 0 of 1 met · 6 without data
- not met: Pays a dividend no dividend per share reported for the last fiscal year
- no data: Payout ratio at most 60% of earnings pays no dividend
- no data: Dividend paid in each of the last 5 fiscal years pays no dividend
- no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
- no data: Dividend per share higher than 5 years ago pays no dividend
- no data: Free cash flow per share covers the dividend pays no dividend
- no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend
Financial strength 4 of 6 met
- not met: Piotroski F-Score at least 7 of 9 2 of 9
- met: Long-term debt no higher than equity 0.07
- met: Current assets cover current liabilities 3.29
- met: Positive equity 8.7B USD
- met: In 5 years, share count up by at most 5% +2.1%
- not met: Free cash flow positive in the last fiscal year −2.1B USD
Piotroski F-Score
2 of 9 Fiscal year 2025
Rank 1 of 100: higher than 1% of 134 peers (All). weak.
Rank 3 of 100: higher than 3% of 19 peers (Sector). weak.
Median Health Care: 7.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
0.07 at fiscal year end
Rank 90 of 100: lower than 90% of 199 peers (All). strong.
Rank 92 of 100: lower than 92% of 18 peers (Sector). strong.
Median Health Care: 0.72
Long-term financial debt divided by equity.
Liquidity (current ratio)
3.29 at fiscal year end
Rank 83 of 100: higher than 83% of 215 peers (All). strong.
Rank 87 of 100: higher than 87% of 26 peers (Sector). strong.
Median Health Care: 1.56
Current assets divided by current liabilities.
Change in share count
+2.1% in 5 years
Rank 37 of 100: lower than 37% of 199 peers (All). medium.
Rank 10 of 100: lower than 10% of 24 peers (Sector). weak.
Median Health Care: −2.7%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
- not met: Profit in the last fiscal year (positive return on assets)
- not met: Positive operating cash flow
- not met: Return on assets higher than the prior year
- met: Operating cash flow higher than net income
- not met: Long-term debt relative to total assets fell
- not met: Liquidity (current assets / current liabilities) rose
- not met: No additional shares (diluted share count did not rise)
- met: Gross margin higher than the prior year
- not met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
- Light green: Revenue grew over 5 years (+19.3% per year), at least as fast as the sector median.
- Light red: Loss in the last fiscal year.
- Light green: Debt not higher than usual in the sector.
- Light red: Profit in 2 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 108.4M USD · Net income −216.2M USD · Net margin −199.5%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 205.8M USD · Net income −255.9M USD · Net margin −124.3%
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 135.1M USD · Net income −384.7M USD · Net margin −284.8%
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 60.2M USD · Net income −514.0M USD · Net margin −853.7%
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 803.4M USD · Net income −747.1M USD · Net margin −93.0%
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 18.5B USD · Net income 12.2B USD · Net margin 66.1%
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 19.3B USD · Net income 8.4B USD · Net margin 43.4%
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 6.8B USD · Net income −4.7B USD · Net margin −68.8%
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 3.2B USD · Net income −3.6B USD · Net margin −110.0%
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 1.8B USD · Net income −3.6B USD · Net margin −198.3%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 2.8B USD · Net income 217.0M USD · Net margin 7.7% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 167.0M USD · Net income −1.2B USD · Net margin −703.6%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 241.0M USD · Net income −1.3B USD · Net margin −530.7%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 1.9B USD · Net income 13.0M USD · Net margin 0.7%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 966.0M USD · Net income −1.1B USD · Net margin −115.9% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 108.0M USD · Net income −971.0M USD · Net margin −899.1%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 142.0M USD · Net income −825.0M USD · Net margin −581.0%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 1.0B USD · Net income −200.0M USD · Net margin −19.7%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 678.0M USD · Net income −826.0M USD · Net margin −121.8% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 389.0M USD · Net income −1.3B USD · Net margin −345.2%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 145.0M USD · Net income −782.0M USD · Net margin −539.3%
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share not available
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share not available
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share not available
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share −1.55 USD
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share −1.96 USD
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 28.29 USD
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 20.12 USD
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share −12.33 USD
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share −9.28 USD
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share −7.26 USD
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Earnings per share −9.53 USD
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Earnings per share not reported separately for Q4
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share −3.07 USD
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share −3.33 USD
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Earnings per share 0.03 USD
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Earnings per share not reported separately for Q4
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Earnings per share −2.52 USD
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Earnings per share −2.13 USD
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Earnings per share −0.51 USD
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share −3.40 USD
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share −1.97 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 55.3 USD gross profit remained.
Operating loss: −158.1% of revenue
Money flow as a table
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 1.9B USD | 100.0% |
| Gross profit | 1.1B USD | 55.3% |
| Cost of revenue | 868.0M USD | 44.7% |
| Operating expenses | 4.2B USD | 213.5% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Margins
The operating margin fell in 5 years from −95.0% to −158.1%.
Gross marginOperating marginNet margin Margins above ±200% hidden (revenue very small relative to the result).- Fiscal year 2016: Gross margin not available · Operating margin not available · Net margin −199.5%
- Fiscal year 2017: Gross margin not available · Operating margin −130.9% · Net margin −124.3%
- Fiscal year 2018: Gross margin not available · Operating margin not available · Net margin not available
- Fiscal year 2019: Gross margin not available · Operating margin not available · Net margin not available
- Fiscal year 2020: Gross margin not available · Operating margin −95.0% · Net margin −93.0%
- Fiscal year 2021: Gross margin 85.8% · Operating margin 72.0% · Net margin 66.1%
- Fiscal year 2022: Gross margin 71.9% · Operating margin 48.9% · Net margin 43.4%
- Fiscal year 2023: Gross margin 31.5% · Operating margin −61.9% · Net margin −68.8%
- Fiscal year 2024: Gross margin 54.8% · Operating margin −121.9% · Net margin −110.0%
- Fiscal year 2025: Gross margin 55.3% · Operating margin −158.1% · Net margin −145.2%
Returns
Return on equity fell in 5 years from −29.2% to −32.6%.
Return on equityReturn on assets- Fiscal year 2016: Return on equity not available · Return on assets not available
- Fiscal year 2017: Return on equity not available · Return on assets −23.6%
- Fiscal year 2018: Return on equity −25.1% · Return on assets −19.6%
- Fiscal year 2019: Return on equity −43.8% · Return on assets −32.3%
- Fiscal year 2020: Return on equity −29.2% · Return on assets −10.2%
- Fiscal year 2021: Return on equity 86.3% · Return on assets 49.5%
- Fiscal year 2022: Return on equity 43.7% · Return on assets 32.3%
- Fiscal year 2023: Return on equity −34.0% · Return on assets −25.6%
- Fiscal year 2024: Return on equity −32.7% · Return on assets −25.2%
- Fiscal year 2025: Return on equity −32.6% · Return on assets −22.9%
Equity and long-term debt
The equity ratio rose in 5 years from 34.9% to 70.1%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.- Fiscal year 2016: Equity −334.8M USD · Long-term debt not available
- Fiscal year 2017: Equity −551.4M USD · Long-term debt not available
- Fiscal year 2018: Equity 1.5B USD · Long-term debt not available
- Fiscal year 2019: Equity 1.2B USD · Long-term debt not available
- Fiscal year 2020: Equity 2.6B USD · Long-term debt not available
- Fiscal year 2021: Equity 14.1B USD · Long-term debt not available
- Fiscal year 2022: Equity 19.1B USD · Long-term debt not available
- Fiscal year 2023: Equity 13.9B USD · Long-term debt not available
- Fiscal year 2024: Equity 10.9B USD · Long-term debt 0.0 USD
- Fiscal year 2025: Equity 8.7B USD · Long-term debt 590.0M USD
Liquidity (current ratio)
The current ratio rose in 5 years from 1.43 to 3.29.
Current ratio- Fiscal year 2016: Current ratio not available
- Fiscal year 2017: Current ratio 4.09
- Fiscal year 2018: Current ratio 7.02
- Fiscal year 2019: Current ratio 7.89
- Fiscal year 2020: Current ratio 1.43
- Fiscal year 2021: Current ratio 1.76
- Fiscal year 2022: Current ratio 2.73
- Fiscal year 2023: Current ratio 3.42
- Fiscal year 2024: Current ratio 3.67
- Fiscal year 2025: Current ratio 3.29
Cash flow
Free cash flow fell in 5 years from 2.0B USD to −2.1B USD.
Operating cash flowCapital expenditureFree cash flow in USD- Fiscal year 2016: Operating cash flow 66.7M USD · Capital expenditure 33.1M USD · Free cash flow 33.6M USD
- Fiscal year 2017: Operating cash flow −331.5M USD · Capital expenditure 58.4M USD · Free cash flow −389.9M USD
- Fiscal year 2018: Operating cash flow −330.9M USD · Capital expenditure 105.8M USD · Free cash flow −436.6M USD
- Fiscal year 2019: Operating cash flow −459.0M USD · Capital expenditure 31.6M USD · Free cash flow −490.5M USD
- Fiscal year 2020: Operating cash flow 2.0B USD · Capital expenditure 67.4M USD · Free cash flow 2.0B USD
- Fiscal year 2021: Operating cash flow 13.6B USD · Capital expenditure 284.0M USD · Free cash flow 13.3B USD
- Fiscal year 2022: Operating cash flow 5.0B USD · Capital expenditure 400.0M USD · Free cash flow 4.6B USD
- Fiscal year 2023: Operating cash flow −3.1B USD · Capital expenditure 707.0M USD · Free cash flow −3.8B USD
- Fiscal year 2024: Operating cash flow −3.0B USD · Capital expenditure 1.1B USD · Free cash flow −4.1B USD
- Fiscal year 2025: Operating cash flow −1.9B USD · Capital expenditure 192.0M USD · Free cash flow −2.1B USD
Share count
The share count rose in 5 years by 2.1% – more new shares were issued than repurchased (dilution).
Diluted share count- Fiscal year 2016: Diluted share count not available
- Fiscal year 2017: Diluted share count not available
- Fiscal year 2018: Diluted share count not available
- Fiscal year 2019: Diluted share count 331.0M
- Fiscal year 2020: Diluted share count 381.0M
- Fiscal year 2021: Diluted share count 431.0M
- Fiscal year 2022: Diluted share count 416.0M
- Fiscal year 2023: Diluted share count 382.0M
- Fiscal year 2024: Diluted share count 384.0M
- Fiscal year 2025: Diluted share count 389.0M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
- Dividend per share
- none pays no dividend
- To shareholders (5 years)
- 5.3B USD 100% through repurchases
- Share count over 5 years
- +2.1% more shares – dilution
What goes back to shareholders
Over 5 years, 5.3B USD went back to shareholders, 100% of it through share repurchases. That is 67% of the free cash flow of those years.
Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD- Fiscal year 2016: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 33.6M USD
- Fiscal year 2017: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow −389.9M USD
- Fiscal year 2018: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 563.0M USD · Free cash flow −436.6M USD
- Fiscal year 2019: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 0.0 USD · Free cash flow −490.5M USD
- Fiscal year 2020: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 1.9B USD · Free cash flow 2.0B USD
- Fiscal year 2021: Dividends paid not available · Share repurchases 857.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 13.3B USD
- Fiscal year 2022: Dividends paid not available · Share repurchases 3.3B USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 4.6B USD
- Fiscal year 2023: Dividends paid not available · Share repurchases 1.2B USD · New shares issued (including employee plans) not available · Free cash flow −3.8B USD
- Fiscal year 2024: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow −4.1B USD
- Fiscal year 2025: Dividends paid not available · Share repurchases 2.0M USD · New shares issued (including employee plans) not available · Free cash flow −2.1B USD
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Sector comparison
Moderna next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | 29.4B USD | +3.6% | 78.8% | 34.0% | 28.9% | 37.5% | 38.5% | 32.1% | 8/9 |
| SYK Stryker Corporation | 25.1B USD | +11.8% | 64.0% | 19.5% | 12.9% | 14.5% | 46.9% | 17.1% | 6/9 |
| DHR Danaher Corporation | 24.6B USD | +2.0% | 59.1% | 19.1% | 14.7% | 6.9% | 62.9% | 21.4% | 7/9 |
| REGN Regeneron Pharmaceuticals | 14.3B USD | +11.0% | – | 24.9% | 31.4% | 14.4% | 77.1% | 28.4% | – |
| VRTX Vertex Pharmaceuticals | 12.0B USD | +14.1% | 86.2% | 34.8% | 32.9% | 21.2% | 72.8% | 26.6% | – |
| ISRG Intuitive Surgical | 10.1B USD | +18.2% | 66.0% | 29.3% | 28.4% | 16.0% | 87.1% | 24.7% | – |
| MRNA Moderna this stock | 1.9B USD | +19.3% | 55.3% | −158.1% | −145.2% | −32.6% | 70.1% | −106.2% | 2/9 |
| NVAX Novavax | 1.1B USD | +18.8% | 93.5% | 40.3% | 39.2% | – | −10.9% | −22.3% | 5/9 |
| IOVA Iovance Biotherapeutics | 263.5M USD | – | 34.3% | −153.1% | −148.4% | −56.0% | 76.5% | −127.6% | – |
| Median of the sector 26 symbols | 44.4B USD | +8.5% | 66.6% | 18.0% | 13.9% | 14.3% | 38.5% | 14.9% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+19.3% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 19.3% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth– per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net margin
Profit marginThe share of revenue that is left as profit after all costs.Example: Profit €60m on €500m revenue → margin 12%.More in the Academy: Lesson revenue, profit and margin−145.2% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 145.16 USD. Five years ago the margin was −93.0%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth0.09 latest balance sheet
Sector Health Care: median 0.66 (49 symbols)
What does this mean? For every 1 USD of equity there is 0.09 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth– Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin2 of 10 fiscal years with a profit
What does this mean? In 2 of the last 10 fiscal years the bottom line showed a profit. 8 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
All figures as a table
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 1.9B | −2.8B | −145.2% | −7.26 | – | – |
| 2024 | Dec 31, 2024 | 3.2B | −3.6B | −110.0% | −9.28 | – | – |
| 2023 | Dec 31, 2023 | 6.8B | −4.7B | −68.8% | −12.33 | – | – |
| 2022 | Dec 31, 2022 | 19.3B | 8.4B | 43.4% | 20.12 | – | – |
| 2021 | Dec 31, 2021 | 18.5B | 12.2B | 66.1% | 28.29 | – | – |
| 2020 | Dec 31, 2020 | 803.4M | −747.1M | −93.0% | −1.96 | – | – |
| 2019 | Dec 31, 2019 | 60.2M | −514.0M | −853.7% | −1.55 | – | – |
| 2018 | Dec 31, 2018 | 135.1M | −384.7M | −284.8% | – | – | – |
| 2017 | Dec 31, 2017 | 205.8M | −255.9M | −124.3% | – | – | – |
| 2016 | Dec 31, 2016 | 108.4M | −216.2M | −199.5% | – | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 145.0M | −782.0M | −539.3% | −1.97 | – | – |
| Q1/26 | Mar 31, 2026 | 389.0M | −1.3B | −345.2% | −3.40 | – | – |
| Q4/25* | Dec 31, 2025 | 678.0M | −826.0M | −121.8% | – | – | – |
| Q3/25 | Sep 30, 2025 | 1.0B | −200.0M | −19.7% | −0.51 | – | – |
| Q2/25 | Jun 30, 2025 | 142.0M | −825.0M | −581.0% | −2.13 | – | – |
| Q1/25 | Mar 31, 2025 | 108.0M | −971.0M | −899.1% | −2.52 | – | – |
| Q4/24* | Dec 31, 2024 | 966.0M | −1.1B | −115.9% | – | – | – |
| Q3/24 | Sep 30, 2024 | 1.9B | 13.0M | 0.7% | 0.03 | – | – |
| Q2/24 | Jun 30, 2024 | 241.0M | −1.3B | −530.7% | −3.33 | – | – |
| Q1/24 | Mar 31, 2024 | 167.0M | −1.2B | −703.6% | −3.07 | – | – |
| Q4/23* | Dec 31, 2023 | 2.8B | 217.0M | 7.7% | – | – | – |
| Q3/23 | Sep 30, 2023 | 1.8B | −3.6B | −198.3% | −9.53 | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $62.6M4 people | −$62.6M |
| 6 months | $00 people | $72.4M6 people | −$72.4M |
| 12 months | $00 people | $81.6M6 people | −$81.6M |
Latest transactions
- Oct 15, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 39,145 shares · $8.6M · SEC
- Oct 14, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 450 shares · $96.4K · SEC
- Oct 14, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 38,774 shares · $8.3M · SEC
- Sep 15, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 40,281 shares · $5.9M · SEC
- Sep 14, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 40,294 shares · $5.8M · SEC
- Sep 10, 2026 Mock James M Chief financial officer (CFO) Open-market sale · 10b5-1 plan 15,000 shares · $2.0M · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +90
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+10
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)46.5
Rel. strength 60 d+273.4%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
More stocks from Health Care
News
Latest news
Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine Yahoo Finance · Oct 26, 17:31
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data Yahoo Finance · Oct 26, 16:58
Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show. Yahoo Finance · Oct 26, 15:52
Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show. Finnhub · Yahoo · Oct 26, 15:52
Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine Finnhub · Yahoo · Oct 26, 15:27
S&P 500 Premarket Movers: Gainers and Losers Before the Open Finnhub · ChartMill · Oct 26, 14:36
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady Yahoo Finance · Oct 26, 14:14
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady Finnhub · Yahoo · Oct 26, 14:14
Posts
No posts on MRNA yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules